TAXUS™ Paclitaxel-Eluting Stent System
Recently, Boston Scientific reached its most significant milestone to date as the TAXUS program moved from its clinical trial stages to commercialization in Europe and other international markets. We have been working toward this moment for years, and we are proud to have introduced this revolutionary new technology.

Operations and R&D worked hard to ensure a successful launch. Our sales force has undergone extensive training to educate clinicians and prepare them for the approval and launch of the TAXUS product in the U.S. The U.S. Food and Drug Administration (FDA) has granted “expedited review” status to the TAXUS product declaring that it may represent a “breakthrough” technology for treating coronary artery disease.

Ongoing clinical trials continue to provide positive data, and we expect this trend to continue as more TAXUS clinical data is collected and analyzed. At the 2002 Transcatheter Cardiovascular Therapeutics (TCT) symposium, we shared the results of the TAXUS II clinical trial with an eager audience. Throughout the year, the results of this and other trials continued to demonstrate the safety and efficacy of the TAXUS product in dramatically reducing coronary restenosis.